



Access status of orphan drugs (ODs) with market name, with orphan designation in force until December 31, 2022


## ODs IN THE EU AND SPAIN




## FINANCED ODs IN SPAIN



## ODs UNFINANCED IN SPAIN



## ODs WITH MARKETING AUTHORISATION WAITING FOR ARRIVAL TO SPAIN



## ADVANCED THERAPIES WITH ORPHAN DESIGNATION



\* Onivyde® is included in the recount of medicines financed by the NHS as of 31/12/2022. During December 2022, Onivyde® was reinstated in Nomenclátor. This product was financed in 2018, but was withdrawn in 2019.

Note: for the preparation of this report, it was not possible to consider drugs that are available in Spain under specific situations and special authorisations within the framework of Royal Decree 1016/2009 (compassionate use, use under conditions other than those authorised or access to foreign medicines), as the data cannot be consulted in public sources.